UBS/CALL/ELI LILLY & CO/850.001/0.01/21.06.24 Stock

Warrant

LLYHNU

CH1327379918

Market Closed - Bid/Ask 11:20:00 2024-05-21 EDT After market 11:15:01
0.11 CHF +57.14% Intraday chart for UBS/CALL/ELI LILLY & CO/850.001/0.01/21.06.24 0.13 +18.18%
Current month+22.22%
1 month+10.00%
Date Price Change
24-05-21 0.11 +57.14%
24-05-15 0.07 +40.00%

Delayed Quote Swiss Exchange

Last update May 21, 2024 at 11:20 am

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ELI LILLY AND COMPANY
Issuer UBS
LLYHNU
ISINCH1327379918
Date issued 2024-02-19
Strike 850 $
Maturity 2024-06-21 (29 Days)
Parity 100 : 1
Emission price 0.3 CHF
Emission volume N/A
Settlement règlement en espèces
Currency CHF

Technical Indicators

Highest since issue 0.35 CHF
Lowest since issue 0.05 CHF
Delta0.34x
Omega 19.21
Premium6.13x
Gearing57.27x
Moneyness 0.9580
Difference Strike 35.89 $
Difference Strike %+4.22%
Spread 0.06 CHF
Spread %37.50%
Theoretical value 0.1300
Implied Volatility 29.21 %
Total Loss Probability 69.44 %
Intrinsic value 0.000000
Present value 0.1300
Break even 864.22 CHF
Theta-0.03x
Vega0.01x
Rho0x

Company Profile

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
More about the company

Ratings for Eli Lilly and Company

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Eli Lilly and Company

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9 USD
Average target price
850.4 USD
Spread / Average Target
+5.92%
Consensus
  1. Stock Market
  2. Warrants
  3. LLYHNU Warrant